In summary, our data strongly indicate that combination treatment targeting both MDM2 and BCL-xL/BCL2 may provide a novel therapeutic option for patients with relapsed or refractory ALL. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.